Dual antiplatelet therapy after minor strokes or high-risk TIA: Evidence from the Austrian stroke registry.

ABSTRACT:

Background and purpose

Three large, randomized trials demonstrated the benefit of short-term dual antiplatelet therapy (DAPT) versus monotherapy after non-cardioembolic minor stroke or high-risk transient ischemic attack (TIA). The aim of this study was to evaluate effects of DAPT versus monotherapy on functional outcomes and safety in a real-life setting.

Methods

Patients with minor stroke (NIHSS <4) or high-risk TIA (ABCD2 score ≥4) of non-cardioembolic origin without major vessel occlusion or revascularization therapy (thrombolysis or thrombectomy) treated between 2018 and 2023 were analyzed based on a prospective nationwide stroke unit registry. Data on risk factors, stroke etiology, admission stroke severity (NIHSS), functional status at 3 months (mRS), and mortality we

SUBMITTER: Krebs S 

PROVIDER: S-EPMC11658963 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature